저자: Max · 외국인
요약 보기
캐시 우드(ARK)가 테슬라·팔란티어 일부를 매도하며 현금을 템퍼스AI(TEM), 더트레이드데스크(TTD), 비트마인(BMNR)에 재배치 중이라는 분석. 세 종목 모두 실적·가격 하락 후 매수한 '역발상 확신' 매수로 해석하며, AI 바이오·디지털 광고 인프라·이더리움 인프라를 2026년 전략 축으로 제시. ARK Innovation ETF는 2025년 들어 약 44% 상승했으나 5년 수익률은 변동성이 크고 시장 하회.
다듬은 글
While the market is fixated on every move from Tesla and Palantir, Cathie Wood is already playing a different game. In a series of moves, she has been trimming her positions in these fan-favorite stocks, rotating millions of dollars out of the very names that made her a household name.
But make no mistake, this isn't a retreat. It's a calculated pivot. She's going all in on a new set of companies, some of which you've probably never heard of. Behind these trades is a hidden strategy that may well define the next wave of disruptive growth. So why is she selling the darlings of the tech world?
And what does she see in a specialized AI healthcare firm, a dominant ad tech giant, and a bold crypto treasury company that nobody else does? We're going to break down the traits, connect the dots, and reveal Cathie Wood's playbook for 2026 and beyond. This is Max from Alpha Forge AI, where we turn market noise into trading signals and hype into context.
Let's start with the sales that are grabbing headlines. Over the past few weeks, ARK Invest has been steadily trimming its positions in both Tesla and Palantir. These aren't massive liquidations, but a pattern of steady, strategic sales. For instance, on November 7th, ARK offloaded Tesla shares worth around $32 million.
We've seen a similar story with Palantir, with sales taking place in October and November. So is Cathie souring on Elon Musk and Alex Karp? Not a chance. It's critical to understand that both Tesla and Palantir are still top-10 holdings in her flagship ARK Innovation ETF, ARKK. This isn't a breakup. It's strategic profit-taking and risk management. After both stocks had a phenomenal run, this looks like a classic Cathie move: trim positions that have grown to an oversized weight in the portfolio, and reallocate that cash into what she sees as the next big thing.
This is the core of her strategy, a constant rotation from today's giants to tomorrow's innovators. I'll show you in a moment how her recent buys paint a crystal-clear picture of where she thinks the next explosive growth is hiding.
The single biggest clue to Cathie's new strategy is her aggressive accumulation of one company: Tempus AI, ticker TEM. On November 6th and 7th, ARK snapped up over 220,000 shares of Tempus, pouring more than $16.2 million into the company.
This wasn't a casual buy. It was a high-conviction move. The purchases came right after the stock dipped following its earnings report, a classic buy-the-dip moment on a stock she believes in deeply. This buying spree has made Tempus AI the fifth-largest holding in the ARK ETF. So what exactly is Tempus, and why is Cathie making it a new cornerstone of her portfolio?
Founded in 2015, Tempus AI sits at the red-hot intersection of healthcare and artificial intelligence. Its mission is to build the world's largest library of clinical and molecular data and create an operating system to make that data useful. Put simply, it uses AI to analyze a patient's genetic information and medical records to help doctors make faster, more personalized, and more effective treatment decisions, especially in cancer care.
Cathie Wood has called AI in healthcare the most underappreciated application of AI, and Tempus seems to be her number one bet on that idea. The business model is compelling. The company makes money from genomic sequencing tests, but the real treasure is the data. Every test feeds its massive database, which it can then license to pharmaceutical companies for drug discovery and clinical trials.
It's a powerful flywheel: more data leads to smarter AI, which leads to better products, which attracts more hospital partners, which generates even more data. This move is part of a broader pivot into genomics, as ARK has also been adding to gene-editing firms like Intellia Therapeutics. The message is loud and clear: Wood believes the fusion of AI and biology is the next frontier.
Now we move from the new cornerstone to the speculative frontier. These next two companies are key to understanding the more aggressive, forward-looking part of Cathie's strategy.
First up is The Trade Desk, ticker TTD. On November 7th, ARK made a significant purchase of over 300,000 shares, valued at around $40.5 million. The buy was telling because it came right after the stock took a hit following its Q3 earnings, showing ARK is ready to pounce on what it sees as short-term weakness in a long-term winner.
The Trade Desk isn't an ad agency. It's a technology company. It runs a large cloud-based platform that lets advertisers manage and optimize data-driven digital ad campaigns across almost every channel you can think of: websites, mobile apps, and connected TV. In a world moving away from tracking cookies, The Trade Desk offers a transparent, auction-based platform for buying ad space. For Cathie, TTD is a pure-play bet on the unstoppable shift of advertising dollars toward programmatic, data-driven platforms.
Then there's the most unusual pick: Bitmine Immersion Technologies, ticker BMNR. On November 6th and 7th, ARK went on a buying spree, snapping up over 240,000 shares of Bitmine for roughly $9 million. Just like the other recent buys, this one came after the stock had taken a significant price drop.
So what is Bitmine? It's a blockchain technology company that pivoted to an aggressive, Ethereum-focused treasury strategy. It has a history in Bitcoin mining and advanced cooling technology, but its main goal now is to acquire and hold a massive amount of Ethereum's native currency, ETH, with the ambition of eventually owning 5% of Ethereum's total supply. For Cathie Wood, BMNR is a way to gain significant leveraged exposure to the Ethereum network within a corporate structure. It's a high-conviction bet that fits ARK's long-held thesis that computing, crypto, and energy are converging.
Let's take a brief pause. If you're getting value from this deep dive, hit that subscribe button to stay informed on the latest AI and investing trends. And ring the bell so you never miss an update.
So what's the hidden strategy here? Selling a bit of Tesla and Palantir isn't about giving up on innovation. It's about rotating capital down the risk curve into the next generation of innovators. The strategy reveals three core pillars for 2026.
**First, AI-powered biology.** The large investment in Tempus AI shows her conviction that the convergence of genomic data and artificial intelligence will revolutionize medicine. This isn't a vague bet on AI. It's a focused investment in a company with a powerful data-driven moat.
**Second, the future of digital infrastructure.** The buys in The Trade Desk and Bitmine are bets on the foundational infrastructure of the digital future. TTD represents the infrastructure for advertising in a post-cookie world, while BMNR represents a bet on the financial and application infrastructure of Web3 centered on the Ethereum network.
**Third, contrarian conviction.** Did you notice the pattern? She bought TEM, TTD, and BMNR after each had experienced a significant price drop. This is the hallmark of a high-conviction investor. While others panic-sell on earnings dips or crypto volatility, she uses pullbacks as a chance to build major positions in companies whose long-term stories remain intact.
In essence, she's rotating from companies that have already seen massive growth into a handpicked group of earlier-stage hypergrowth companies she believes could become the next industry titans. It's a move from established disruptors to emerging ones.
There you have it. Cathie Wood's recent portfolio shift is far from random. It's a disciplined, forward-looking strategy to rotate profits from mature winners into what she sees as undervalued next-generation leaders in AI, healthcare, ad tech, and the crypto economy.
The strategy carries real risks. The ARK Innovation ETF is up an impressive 44% year-to-date in 2025, outpacing the S&P 500. However, looking back five years, the fund's performance has been volatile and has trailed the broader market. That's a reminder that these high-growth bets can be a wild ride. The moves into Tempus AI, The Trade Desk, and Bitmine are bold, contrarian, and quintessentially Cathie Wood. She is doubling down on her vision of the future, even if it means weathering serious short-term turbulence.
Now I want to hear from you. What do you think of this major portfolio shift? Are you buying what Cathie is buying, or do you think trimming Tesla is a mistake? Let me know your thoughts on TEM, TTD, and BMNR in the comments below.
As always, this is not financial advice. I'm not a financial adviser, just a Forge rat hammering out signals. Remember, the market is the forge, and your research is the hammer. Thanks for watching, and see you in the forge.
Comments 0